IXJ:NYE-iShares Global Healthcare ETF (USD)

ETF | Health |

Last Closing

USD 92.57

Change

+1.22 (+1.34)%

Market Cap

N/A

Volume

0.32M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-05 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.41 (+0.96%)

USD 37.80B
FHLC Fidelity® MSCI Health Care In..

+0.84 (+1.20%)

USD 2.66B
FXH First Trust Health Care AlphaD..

+0.80 (+0.73%)

USD 1.07B
XHE SPDR® S&P Health Care Equipme..

+1.02 (+1.07%)

USD 0.21B
IDNA iShares Genomics Immunology an..

+0.78 (+3.48%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.67 (+2.03%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.37 (+0.36%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.59 (+1.93%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.21 (+1.95%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.79 (+3.41%)

USD 6.89M

ETFs Containing IXJ

IXJ:AU iShares Global Healthcare.. 99.95 % 0.00 %

-1.61 (-1.10%)

USD 1.43B
XHC:CA iShares Global Healthcare.. 0.00 % 0.65 %

+0.86 (+-1.10%)

CAD 0.54B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.68% 52% F 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.68% 52% F 84% B
Trailing 12 Months  
Capital Gain 2.31% 19% F 40% F
Dividend Return 1.42% 94% A 23% F
Total Return 3.73% 24% F 31% F
Trailing 5 Years  
Capital Gain 32.05% 62% D 64% D
Dividend Return 7.80% 79% B- 22% F
Total Return 39.85% 71% C- 60% D-
Average Annual (5 Year Horizon)  
Capital Gain 5.52% 67% D+ 52% F
Dividend Return 6.48% 67% D+ 48% F
Total Return 0.96% 74% C 23% F
Risk Return Profile  
Volatility (Standard Deviation) 13.18% 81% B- 71% C-
Risk Adjusted Return 49.19% 81% B- 63% D
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike